Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

This study has been completed.

Sponsor:

Information provided by:

Walter Reed Army Medical Center

ClinicalTrials.gov Identifier:

NCT00413751

First received: December 19, 2006

Last updated: NA

Last verified: December 2006

History: No changes posted

Tracking Information

First Received Date ^ICMJE

December 19, 2006

Last Updated Date

December 19, 2006

Start Date ^ICMJE

Not Provided

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

No Changes Posted

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

Official Title ^ICMJE

Not Provided

Brief Summary

The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.

Detailed Description

Not Provided

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Time Perspective: Longitudinal
Time Perspective: Prospective

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Not Provided

Study Population

Not Provided

Condition ^ICMJE

Healthy

Intervention ^ICMJE

Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)

Study Groups/Cohorts

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

Not Provided

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Adult active duty personnel between 18 and 50 years of age with best corrected visual acuity of 20/20 or better.

Exclusion Criteria:

Patients not meeting above stated age criteria
Females that are pregnant or lactating (non pregnant females of childbearing potential will have pregnancy test prior to participating in study)
History of serious ocular, neurological, cardiovascular disease
History of severe systemic disease
History of arrhythmias or high blood pressure
Patients currently taking any type of ocular or systemic medications except multivitamins.
Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil defect.

Sex/Gender

Sexes Eligible for Study:

All

Ages

18 Years to 50 Years (Adult)

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Listed Location Countries ^ICMJE

United States

Removed Location Countries

Administrative Information

NCT Number ^ICMJE

NCT00413751

Other Study ID Numbers ^ICMJE

WRAMC WU #03-23004

Has Data Monitoring Committee

Not Provided

U.S. FDA-regulated Product

Not Provided

Plan to Share Data

Not Provided

IPD Description

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Walter Reed Army Medical Center

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

KRAIG S. BOWER, MD

Walter Reed Army Medical Center

PRS Account

Walter Reed Army Medical Center

Verification Date

December 2006

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top